Alaska Clinical Research Center
Alaska Clinical Research Center, LLC (ACRC) is an educational and research affiliate
of Alaska Urological Institute, APC. It is a separate site and entity founded by a team of
urologists dedicated to conducting clinical research trials in urology.
Our primary objective is to provide optimal patient care by giving patients access to a broad spectrum of treatment alternatives, and a greater understanding of new therapies.
Our primary objective is to provide optimal patient care by giving patients access to a broad spectrum of treatment alternatives, and a greater understanding of new therapies.
All Research Studies (on ClinicalTrials.gov)
Therapeutic Areas:
- Urology
- Urogynecology
- Urologic Oncology
- Nephrology
- Sexual Dysfunction
Our research is specialized to any of our therapeutic specialties, and encompass clinical trials in all phases of study. (Phases II, III, and IV).
- Erectile Dysfunction
- Hypogonadism
- Prostate Cancer
- Prostatitis
- Benign Prostatic Hypertrophy (BPH)
- Pyelonephritis / Urinary Tract Infections
- complicated & uncomplicated - Bladder Cancer
- Urolithiasis
- Urinary Incontinence
- Interstitial Cystitis
Our center has worked with the following:
Sponsors:
Merck, Bristol-Meyers Squibb, Eli Lilly, Active Biotech Astellas, AstraZeneca, ALZA Corporation, Amgen, Praecis Pharmaceuticals, Schering-Plough, TAP Pharmaceuticals, Uroplasty, Cellegy, Lexigen, Atrix Laboratories, Pharmacia, Abbott, Boehringer Ingelheim, Bayer, Novartis, Takeda, Millenium
Merck, Bristol-Meyers Squibb, Eli Lilly, Active Biotech Astellas, AstraZeneca, ALZA Corporation, Amgen, Praecis Pharmaceuticals, Schering-Plough, TAP Pharmaceuticals, Uroplasty, Cellegy, Lexigen, Atrix Laboratories, Pharmacia, Abbott, Boehringer Ingelheim, Bayer, Novartis, Takeda, Millenium
CRO’s:
PPD Development, Quintiles, Covance, Phoenix International, Kendle, The Phoenix, i3 Research, Inc., ILEX Oncology, Diagnostic Oncology
Browse the active studies below to learn about eligibility for patient participation.
| Study of Immunotherapy to Treat Advanced Prostate Cancer | |
| Condition: | Prostate Cancer |
| Interventions: | Drug: Ipilimumab; Drug: Placebo |
| Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer | |
| Condition: | Prostatic Neoplasms |
| Interventions: | Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone |
| Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | |
| Condition: | Prostate Cancer |
| Interventions: | Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone |
| The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Auxilium Pharmaceuticals, Inc. | |
| Phase 3 study will start in Fall, 2010-05-10 | |
| Condition: | |
| Interventions: | |
| A Phase 3 Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer (Prospect Study) | |
| A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or
Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer. |
|
| Condition: | Metastatic Prostate Cancer |
| Interventions: | Drug: Vaccine + GM-CSF; Drug: Vaccine + Placebo; Drug: Placebo/Placebo |
| A Phase 2 Study of MDV3100 (ASP9785) vs Bicalutamide to Treat Metastatic Prostate Cancer (Terrain Study) | |
| A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP8785) vs. Bicalutamide in Castrate
Men with Metastatic Prostate Cancer. |
|
| Condition: | Metastatic Prostate Cancer |
| Interventions: | Drug: MDV3100; Drug: Bicalutamide |
| Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | |
| An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic
Castration-Resistant Prostate Cancer. |
|
| Condition: | Prostate Cancer |
| Interventions: | Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone |
| Study of TAK-700 and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy | |
| A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo
Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. The Elm.Pc - Studies for Metastatic Prostate Cancer |
|
| Condition: | Metastatic Prostate Cancer |
| Interventions: | Drug: TAK-700 (Orteronel); Drug: Prednisone; Drug: Placebo |
| Study of TAK-700 and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer after Chemotherapy | |
| A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo
Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Docetaxel-based Therapy. The Elm.Pc - Studies for Metastatic Prostate Cancer |
|
| Condition: | Metastatic Prostate Cancer |
| Interventions: | Drug: TAK-700; Drug: Prednisone; Drug: Placebo |
| Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer | |
| ACTIVE BUT CLOSED TO ENROLLMENT |
|
| Condition: | Prostatic Neoplasms |
| Interventions: | Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone |
| Study of Immunotherapy to Treat Advanced Prostate Cancer | |
| Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs. Placebo in Asymptomatic or
Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer. |
|
| Condition: | Prostate Cancer |
| Interventions: | Drug: Ipilimumab; Drug: Placebo |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (EMBARC-RF) | |
| This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately
120 investigational sites worldwide. Subjects with either recurrent or refractory NMIBC (Ta high grade, T1 low or high
grade, CIS) will be eligible for participation in this study. |
|
| Condition: | Non-Muscle Invasive Recurrent or Refractory Bladder Cancer |
| Interventions: | Drug: EN3348; Drug: Mitomycin |
| A Study to Assess Efficacy and Safety With VESIcare® to Improve Urinary Continence in Subjects After Robotic Assisted Radical Prostatectomy | |
| A Randomized, Double-Blind, Parallel, Placebo Controlled, Phase 4, Multi-center Study to Assess Efficacy and Safety of
VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical
Prostatectomy. |
|
| Condition: | Urinary Incontinence after Robotic Radical Prostatectomy |
| Interventions: | Drug: VESIcare; Drug: Placebo |